Early stage breast cancer treatment and prognostic factors

Abstract

SummaryDevelopments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients.

Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis

“…Without timely treatment, breast cancer easily metastasize to heart, brain, lung and other important organs, posing a serious threat to human life and health (4). The survival rate of breast cancer patients has improved due to the continuous progress of surgical treatment, radiotherapy and chemotherapy and the wide application of molecular targeting and immunotherapy, but there are still approximately 20-30% of patients who relapse and develop distant metastasis (5)(6)(7). The study of biomarkers can predict the risk and metastasis of malignant tumors, which is helpful for the treatment of breast cancer (8).…”

Post San Antonio Breast Cancer Symposium

“…Regarding systemic treatment in the adjuvant setting, Marija Balic [2] presents three prospective trials using extended endocrine therapy (DATA, IDEAL, NS-ABP-B42) with unexpected results, at least for some of us. The use of bisphosphonates in adjuvant therapy has been addressed in the TEAMIIb trial and Balic also presents data of patients with HER2-enriched breast cancer in the neoadjuvant (NSABP-B52; standard treatment with or without endocrine therapy) and in an adjuvant setting (only stage I; APT trial using paclitaxel weekly as backbone as well as adjuvant TDM1 versus trastuzumab using pertuzumab in both groups).…”